Page last updated: 2024-12-08

cupric glycinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cupric glycinate: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3032611
SCHEMBL ID119088
MeSH IDM0070085

Synonyms (41)

Synonym
copper glycine
cupric aminoacetate
glycine, copper(2+) salt (2:1)
copper, bis(glycinato(1-))-
copper glycinate
cupric glycinate
copper, bis(glycinato)-
copper diglycinate
copper aminoacetate
bis(aminoacetato)copper
bis(glycinato)copper
nsc-162736
AKOS005067822
bis(glycinato-n,o)copper
unii-68vav8qid7
nsc 162736
einecs 236-783-2
68vav8qid7 ,
copper bis(glycinate)
copper, bis(glycinato-kappan,kappao)-
copper(ii) bisglycinate
copper, bis(glycinato-n,o)-
32817-15-5
einecs 251-238-9
cupric bisglycinate [mi]
copper glycinate [inci]
copper(ii) glycinate
copper glycinate [who-dd]
cupric bisglycinate
cupric glycinate [green book]
SCHEMBL119088
VVYPIVJZLVJPGU-UHFFFAOYSA-L
mfcd00065114
DTXSID40893690
DB11509
copper(ii) biglycinate
copper(ii) diglycinate
copper;2-aminoacetate
AS-17297
Q17377051
SY107795

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Moreover, we show that the toxic and protective CuBD phenotypes are associated with differences in Cu binding and reduction."( Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.
Beyreuther, K; Cappai, R; Galatis, D; Masters, CL; McKinstry, WJ; Multhaup, G; Parker, MW; Pipkorn, R; White, AR, 2002
)
0.31

Bioavailability

ExcerptReferenceRelevance
"Sixty Angus (n = 29) and Angus-Sim-mental cross (n = 31) steers, averaging 9 mo of age and 277 kg of initial BW, were used in a 148-d study to determine the bioavailability of copper glycinate (CuGly) relative to feed-grade copper sulfate (CuSO(4)) when supplemented to diets high in S and Mo."( Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum.
Hansen, SL; Legleiter, LR; Lloyd, KE; Schlegel, P; Spears, JW, 2008
)
0.35
" Bioavailability was then evaluated by analyzing plasma samples of horses supplemented with glycinates-rich feed."( Determination of Zn-, Cu- and Mn-glycinate complexes in feed samples and in-vitro and in-vivo assays to assess their bioaccessibility in feed samples.
Ionescu, C; Lobinski, R; Oguey, S; Vacchina, V, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (37.04)18.7374
1990's6 (22.22)18.2507
2000's7 (25.93)29.6817
2010's4 (14.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other27 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]